US5955588A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Non-thrombogenic coating composition and methods for using same
Assignee: Covidien LP
•
Filing: 1998-09-22
•
Granted: 1999-09-21
•
Expires: 2018-09-22
Abstract
Abstract The present invention provides an anti-thrombogenic coating composition for blood-contacting surfaces. The coating comprises a covalent complex of from 1 to 30 hydrophobic silyl moieties of Formula I: wherein R1 is a C1-8 alkyl or C6-32 aryl group, each R2 is independently selected from the group consisting of C1-8 alkyl and C6-32 aryl, R3 is N or O, and n is a number from 1 to 10, directly bound to a heparin molecule via covalent bonding.
Inventors
- 👤 Ray Tsang
- 👤 Shigemasa Osaki
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:28
CPC Classifications
C; C08; C08G; C08G77/00; C08G77/60; A; A61; A61L; A61L33/00; A61L33/0005; A61L33/0011; A61L33/0029; C08B; C08B37/00; C08B37/006; C08B37/0063; C08B37/0075
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
79 words
A non-thrombogenic coating composition for blood-contacting surfaces, said composition comprising a covalent complex of from 1 to 30 hydrophobic silyl moieties of Formula I: ##STR7## wherein R 1 is a C 1-8 alkyl or C 6-32 aryl group, each R 2 is independently selected from the group consisting of C 1-8 alkyl and C 6-32 aryl R 3 is N or O, and n is a number from 1 to 10 directly bound to sodium heparin via covalent bonding.
Claim 2
Dependent Claim
79 words
A non-thrombogenic coating composition for blood-contacting surfaces, said composition comprising a covalent complex of from 1 to 30 hydrophobic silyl moieties of Formula I: ##STR7## wherein R 1 is a C 1-8 alkyl or C 6-32 aryl group, each R 2 is independently selected from the group consisting of C 1-8 alkyl and C 6-32 aryl R 3 is N or O, and n is a number from 1 to 10 directly bound to sodium heparin via covalent bonding.
Claim 3
Dependent Claim
19 words
The composition according to claim 1, wherein said hydrophobic silyl moieties bind to said surfaces via hydrophobic bonding interactions.
Claim 4
Dependent Claim
23 words
The composition according to claim 1, wherein said complex comprises from 2 to 25 hydrophobic silyl moieties covalently bound to one heparin molecule.
Claim 5
Dependent Claim
19 words
The composition according to claim 1, wherein R 1 is benzyl in said hydrophobic silyl moiety of Formula I.
Claim 6
Dependent Claim
21 words
The composition according to claim 1, wherein each R 2 is an alkyl in said hydrophobic silyl moiety of Formula I.
Claim 7
Dependent Claim
20 words
The composition according to claim 1, wherein n is 2 or 3 in said hydrophobic silyl moiety of Formula I.
Claim 8
Dependent Claim
11 words
The composition according to claim 1, wherein said complex is benzyl-bis(dimethylsilylmethyl)!-(N-heparinyl)-carbamate.
Claim 9
Dependent Claim
11 words
The composition according to claim 1, wherein said complex is benzyl-tris(dimethylsilylmethyl)!-(N-heparinyl)-carbamate.
Claim 10
Dependent Claim
87 words
A non-thrombogenic medical device comprising surfaces for contacting blood, said surfaces having coated thereon a non-thrombogenic coating composition comprising a covalent complex of from 1 to 30 hydrophobic silyl moieties of Formula I: ##STR8## wherein R 1 is a C 1-8 alkyl or C 6-32 aryl group, each R 2 is independently selected from the group consisting of C 1-8 alkyl and C 6-32 aryl, R 3 is N or O, and n is a number from 1 to 10 directly bound to heparin via covalent bonding.
Claim 11
Dependent Claim
87 words
A non-thrombogenic medical device comprising surfaces for contacting blood, said surfaces having coated thereon a non-thrombogenic coating composition comprising a covalent complex of from 1 to 30 hydrophobic silyl moieties of Formula I: ##STR8## wherein R 1 is a C 1-8 alkyl or C 6-32 aryl group, each R 2 is independently selected from the group consisting of C 1-8 alkyl and C 6-32 aryl, R 3 is N or O, and n is a number from 1 to 10 directly bound to heparin via covalent bonding.
Claim 12
Dependent Claim
19 words
The device according to claim 9, wherein said hydrophobic silyl moieties bind to said surfaces via hydrophobic bonding interactions.
Claim 13
Dependent Claim
23 words
The device according to claim 9, wherein said complex comprises from 2 to 25 hydrophobic silyl moieties covalently bound to one heparin molecule.
Claim 14
Dependent Claim
19 words
The device according to claim 9, wherein R 1 is benzyl in said hydrophobic silyl moiety of Formula I.
Claim 15
Dependent Claim
21 words
The device according to claim 9, wherein each R 2 is an alkyl in said hydrophobic silyl moiety of Formula I.
Claim 16
Dependent Claim
20 words
The device according to claim 9, wherein n is 2 or 3 in said hydrophobic silyl moiety of Formula I.
Claim 17
Dependent Claim
11 words
The device according to claim 9, wherein said complex is benzyl-bis(dimethylsilylmethyl)!-(N-heparinyl)-carbamate.
Claim 18
Dependent Claim
11 words
The device according to claim 9, wherein said complex is benzyl-tris(dimethylsilylmethyl)!-(N-heparinyl)-carbamate.
Claim 19
Dependent Claim
41 words
The device according to claim 9, wherein said device is selected from the group consisting of oxygenators, oxygenator circuits, heart-lung bypass circuits, blood gas exchange devices, blood filters, artificial blood vessels, artificial valves, prosthetics, stents, catheters, heat exchangers, and hypodermic needles.
Claim 20
Independent Claim
91 words
A method for rendering blood-contacting surfaces of a medical device non-thrombogenic, said method comprising coating said surfaces with a non-thrombogenic coating composition comprising a covalent complex of from 1 to 30 hydrophobic silyl moieties of Formula I: ##STR9## wherein R 1 is a C 1-8 alkyl or C 6-32 aryl group, each R 2 is independently selected from the group consisting of C 1-8 alkyl and C 6-32 aryl, R 3 is N or O, and n is a number from 1 to 10 directly bound to heparin via covalent bonding.
Claim 21
Independent Claim
91 words
A method for rendering blood-contacting surfaces of a medical device non-thrombogenic, said method comprising coating said surfaces with a non-thrombogenic coating composition comprising a covalent complex of from 1 to 30 hydrophobic silyl moieties of Formula I: ##STR9## wherein R 1 is a C 1-8 alkyl or C 6-32 aryl group, each R 2 is independently selected from the group consisting of C 1-8 alkyl and C 6-32 aryl, R 3 is N or O, and n is a number from 1 to 10 directly bound to heparin via covalent bonding.
Claim 22
Dependent Claim
19 words
The method according to claim 18, wherein said hydrophobic silyl moieties bind to said surfaces via hydrophobic bonding interactions.
Claim 23
Dependent Claim
23 words
The method according to claim 18, wherein said complex comprises from 2 to 25 hydrophobic silyl moieties covalently bound to one heparin molecule.
Claim 24
Dependent Claim
19 words
The method according to claim 18, wherein R 1 is benzyl in said hydrophobic silyl moiety of Formula I.
Claim 25
Dependent Claim
21 words
The method according to claim 18, wherein each R 2 is an alkyl in said hydrophobic silyl moiety of Formula I.
Claim 26
Dependent Claim
20 words
The method according to claim 18, wherein n is 2 or 3 in said hydrophobic silyl moiety of Formula I.
Claim 27
Dependent Claim
11 words
The method according to claim 18, wherein said complex is benzyl-bis(dimethylsilylmethyl)!-(N-heparinyl)-carbamate.
Claim 28
Dependent Claim
11 words
The method according to claim 18, wherein said complex is benzyl-tris(dimethylsilylmethyl)!-(N-heparinyl)-carbamate.
Claim 29
Dependent Claim
26 words
The method according to claim 18, which further comprises the step of solubilizing said complex in a solvent prior to said step of coating said surface.
Claim 30
Dependent Claim
24 words
The method according to claim 18, wherein said step of coating said surface comprises dipping said surface into said coating composition comprising said complex.
Claim 31
Dependent Claim
24 words
The method according to claim 18, wherein said step of coating said surface comprises pumping said coating composition comprising said complex onto said surface.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-09-20 | 2003-03-22 | 2003-09-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-09-20 | 2007-03-22 | 2007-09-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-09-20 | 2011-03-22 | 2011-09-21 | $7700.00 | Window Closed / Lapsed |